Published: 2021-08-24

Analysis of the variations in price of anti-glaucoma eye preparations available in Indian pharmaceutical market

Sonu Kumar, Anupam Chandra, Akash Prasad Chandra, Uma Shankar Prasad Kesari


Background: The aim of the study was to analyze the percentage cost variations among different brands of the commonly prescribed anti–glaucoma drugs.

Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2018 edition Drug Today April to June 2018 Vol-1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of each eye drop was calculated. At last the cost ratio and percentage cost variation of various brands was compared.

Results: Percentage variation in cost for anti-glaucoma eye preparations marketed in india was found to be eye drop timolol maleate (0.5%) of 5 ml:263.63, eye drop dorzolamide (2%) of 5 ml:9.77, eye drop pilocarpine (2%) of 5 ml:160.40, eye drop Betaxolol (0.5%) of 5 ml:56.54, eye drop Latanoprost (50 mcg/ml) of 2.5ml:135.88, eye drop Brimonidine tartarate (0.15%) of 5 ml:183.9, eye drop Levobunolol (5 mg/ml) of 5 ml:32.38.

Conclusions: Glaucoma is the most common ocular disease and eye drops are to be prescribed for prolonged period. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.


Glaucoma, Percentage cost variation, Cost ratio

Full Text:



“Facts About Glaucoma’’. National Eye Institute. Accessed on 29th March 2016.

Mantravadi AV, Vadhar N. “Glaucoma”. Primary Care. Saunders (Elsevier). 2015;42(3):437-49.

Mishima S, Masuda K, Tamura T. In: Drugs Influencing Aqueous Humor Formation and Drainage Dikstein S (ed): Drugs and Ocular Tissues. International Society for Eye. 1977;128-287.

Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous Humor Dynamics: A Review often Ophthalmol J. 2010;4:52-9.

Thomas R, Loiblks, Parikh R. Evaluation of a glaucoma patient. Indian J Ophthalmol. 2011;59(1):S43-52.

Smith SD, Singh K, Lin SC, Chen TC, Francis BA et al. Evaluation of the Anterior Chamber Angle in Glaucoma. A Report by the American Academy of Ophthalmology. Ophthalmology. 2013;120:1985-97.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patients cost-sharing trends affects adherence and outcomes; a literature review: PT. 2012;37:45-55.

Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004;17:80-3.

Sanchez LS. Pharmacoeconomics: Principles, methods and applications. In: Dipiro JT, Talbert RL, Yee GC.

Das SC, Mandal M, Mandal SC. A critical study on a vailability and price variation between different brands:impact on access to medicine. Indian J Pharm Sci. 2007;69(1):160-3.

Chawan VS, Gawand K V, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Pharmacol. 2014:3:954-7.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Hasen NK, editors. A Textbook of Clinical Pharmacy Practice. Orient Longman. 2004;723.

Creese A, Kotwani A, Kutzin J, Pillay A. Evaluating pharmaceuticals for Health policy in low and middle –income country settings. In: Free mantle N, Hill S, eds. Evaluating pharmaceuticals for Health policy and reimbursement. Blackwell Publication. 2004;227-43.

Mahal A, Karan A, Engelgau M. The Economic Implications of Non-communicable Disease for India. Washington, DC: World Bank. 2010. ITIONANDPOPULATION/Resourses/281627-1095698140167/Economic Implications of NCD for in dia.pdf. Accessed on 1st May, 2021.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51:13-6.

Drug cost control Order, 2013 Government of India. Accessed on 1st May, 2021.

Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins: The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.

Kumar L. Cost variation analysis of antimalarial drugs available in India. Int J Res Med Sci. 2017;5(9):4051-4.